|
|
- 2018
Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe PsoriasisKeywords: Cost of illness, Drug administration schedule, Insurance, Psoriasis, Ustekinumab Abstract: The continuous use of biologic agents in the treatment of psoriasis has been reported to result in successful and sustained therapeutic effects and safety. However, some patients choose intermittent and repetitive treatment
|
